Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.50B | 1.76B | 2.23B | 2.02B | 1.30B |
Gross Profit | 301.22M | 336.05M | 462.67M | 479.01M | 323.53M |
EBITDA | 70.71M | 25.15M | 166.13M | 130.62M | 39.83M |
Net Income | 16.08M | -113.47M | 87.46M | 277.30M | 33.10M |
Balance Sheet | |||||
Total Assets | 2.08B | 2.16B | 2.39B | 2.04B | 1.38B |
Cash, Cash Equivalents and Short-Term Investments | 167.81M | 173.76M | 148.13M | 219.74M | 178.11M |
Total Debt | 401.95M | 496.20M | 336.55M | 155.22M | 76.47M |
Total Liabilities | 1.29B | 1.38B | 1.51B | 1.26B | 854.27M |
Stockholders Equity | 791.41M | 773.01M | 896.94M | 786.58M | 517.90M |
Cash Flow | |||||
Free Cash Flow | 75.72M | -133.59M | -155.25M | -204.02M | 25.68M |
Operating Cash Flow | 98.81M | -62.65M | -37.93M | -103.45M | 52.22M |
Investing Cash Flow | 4.43M | -54.47M | -153.14M | 65.02M | -59.81M |
Financing Cash Flow | -101.32M | 147.12M | 125.30M | 59.35M | -5.51M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | HK$623.49M | 6.99 | 11.96% | 4.32% | 17.93% | 36.82% | |
57 Neutral | HK$1.48B | -11.51 | -9.03% | ― | -30.60% | 28.61% | |
52 Neutral | HK$527.96M | 13.92 | 4.40% | ― | -2.77% | ― | |
50 Neutral | HK$1.42B | -2.02 | -32.31% | ― | -8.56% | -14.84% | |
47 Neutral | HK$836.99M | -3.25 | -20.74% | ― | 11.43% | 4.88% | |
41 Neutral | HK$298.19M | -1.70 | 199.66% | ― | 6.10% | -115.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Austar Lifesciences Ltd. announced its interim results for the six months ended June 30, 2025, showing a decrease in revenue from RMB 700,919,000 in 2024 to RMB 661,905,000 in 2025. Despite the revenue decline, the company reported a significant increase in profit before income tax, rising from RMB 9,186,000 in 2024 to RMB 30,303,000 in 2025, indicating improved operational efficiency. The profit attributable to the owners of the company also saw a substantial rise, reflecting a positive impact on the company’s financial health and potential benefits for stakeholders.
The most recent analyst rating on (HK:6118) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Austar Lifesciences Ltd. stock, see the HK:6118 Stock Forecast page.
Austar Lifesciences Limited, a company incorporated in the Cayman Islands, has announced an update to its board of directors and their roles, effective from August 26, 2025. The board comprises executive, non-executive, and independent non-executive directors, with Mr. Ho Kwok Keung, Mars serving as the Chairman and CEO. The announcement also details the membership of five board committees, highlighting the leadership and participation of each director in these committees.
The most recent analyst rating on (HK:6118) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Austar Lifesciences Ltd. stock, see the HK:6118 Stock Forecast page.
Austar Lifesciences Ltd. announced a change in its executive leadership with the resignation of Mr. Chen Yuewu as an executive director and his replacement by Mr. Bian Ce. Mr. Bian, who has extensive experience in the pharmaceutical equipment industry, has been with the company since 2022 and has held senior roles, contributing significantly to the company’s growth. Despite a past legal issue regarding trade secrets, the company is confident in Mr. Bian’s leadership abilities and ethical standards, viewing his appointment as a positive step for the company’s future operations and market positioning.
The most recent analyst rating on (HK:6118) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Austar Lifesciences Ltd. stock, see the HK:6118 Stock Forecast page.
Austar Lifesciences Ltd. has announced a board meeting scheduled for August 26, 2025, to review and approve the unaudited interim results for the first half of the year and consider the declaration of an interim dividend. This meeting is significant as it could impact the company’s financial strategy and shareholder returns, potentially influencing its market position and investor confidence.
Austar Lifesciences Ltd. has announced a significant increase in profits for the first half of 2025, expecting a profit of RMB23-25 million compared to RMB5.88 million in the same period of 2024. This growth is attributed to strategic efficiency improvements and exchange gains, highlighting the company’s focus on sustainable long-term value creation.
Austar Lifesciences Limited has announced updates to the terms of reference for its Risk Management Committee (RMC), which is a part of the company’s Board of Directors. The RMC is responsible for overseeing risk management practices and will consist of at least three members appointed by the Board. The chairman of the RMC is also appointed by the Board, and the committee has the authority to invite other directors or executives to attend meetings if their presence is deemed beneficial for fulfilling the committee’s duties. This update reflects the company’s ongoing commitment to robust governance and risk management practices, which are crucial for maintaining its operational integrity and stakeholder confidence.
Austar Lifesciences Limited, incorporated in the Cayman Islands, has announced an update to the terms of reference for its Audit Committee, effective from June 19, 2025. The Audit Committee will consist of at least three non-executive directors, with a majority being independent non-executive directors possessing appropriate professional qualifications or financial expertise. This update aims to enhance the governance and oversight functions of the committee, potentially strengthening the company’s compliance and financial management practices.
Austar Lifesciences Ltd. has announced the terms of reference for its Nomination Committee, which is responsible for overseeing the selection and appointment of directors. The committee will consist of at least three members, with a majority being independent non-executive directors, and will include at least one member of a different gender. This move is aimed at ensuring diversity and independence in the company’s governance structure, potentially enhancing its industry positioning and stakeholder confidence.